investorscraft@gmail.com

TScan Therapeutics, Inc. (TCRX)

Previous Close
$1.40
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)71.374998
Intrinsic value (DCF)0.66-53
Graham-Dodd Methodn/a
Graham Formula85.055975

Company Information

830 Winter Street
Waltham, MA 02451
United States
Phone: 857 399 9500
Industry: Biotechnology
Sector: Healthcare
CEO: Dr. Gavin MacBeath Ph.D.
Full Time Employees: 200

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

HomeMenuAccount